Nautilus Biotechnology (NASDAQ:NAUT) Major Shareholder Sells $11,750,000.00 in Stock

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) major shareholder Ah Equity Partners Bio Ii, L.L sold 5,000,000 shares of the stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $2.35, for a total transaction of $11,750,000.00. Following the completion of the transaction, the insider directly owned 971,885 shares in the company, valued at $2,283,929.75. This trade represents a 83.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Nautilus Biotechnology Price Performance

NASDAQ NAUT opened at $2.39 on Friday. The firm’s fifty day moving average price is $2.86 and its 200 day moving average price is $2.46. The company has a market capitalization of $303.72 million, a price-to-earnings ratio of -5.20 and a beta of 0.75. Nautilus Biotechnology, Inc. has a 12 month low of $0.62 and a 12 month high of $4.31.

Nautilus Biotechnology (NASDAQ:NAUT) last posted its earnings results on Tuesday, April 28th. The company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02.

Institutional Trading of Nautilus Biotechnology

Hedge funds have recently made changes to their positions in the company. Garde Capital Inc. acquired a new stake in shares of Nautilus Biotechnology in the 4th quarter worth $35,000. Hudson Bay Capital Management LP acquired a new stake in shares of Nautilus Biotechnology in the 4th quarter worth $37,000. Ashton Thomas Private Wealth LLC acquired a new stake in shares of Nautilus Biotechnology in the 3rd quarter worth $38,000. Qube Research & Technologies Ltd acquired a new stake in shares of Nautilus Biotechnology in the 2nd quarter worth $45,000. Finally, Virtu Financial LLC lifted its stake in shares of Nautilus Biotechnology by 19.6% in the 4th quarter. Virtu Financial LLC now owns 23,532 shares of the company’s stock worth $46,000 after acquiring an additional 3,849 shares during the period. Institutional investors and hedge funds own 50.71% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Nautilus Biotechnology in a research report on Tuesday, April 21st. Guggenheim raised their price objective on shares of Nautilus Biotechnology from $2.50 to $4.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $4.00.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.

Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.